| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1512 | 2012 |
| Organoid profiling identifies common responders to chemotherapy in pancreatic cancer H Tiriac, P Belleau, DD Engle, D Plenker, A Deschênes, TDD Somerville, ... Cancer discovery 8 (9), 1112-1129, 2018 | 866 | 2018 |
| CD74–NRG1 Fusions in Lung Adenocarcinoma L Fernandez-Cuesta, D Plenker, H Osada, R Sun, R Menon, F Leenders, ... Cancer discovery 4 (4), 415-422, 2014 | 290 | 2014 |
| Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors S Ortiz-Cuaran, M Scheffler, D Plenker, L Dahmen, AH Scheel, ... Clinical Cancer Research 22 (19), 4837-4847, 2016 | 260 | 2016 |
| Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors J Fassunke, F Müller, M Keul, S Michels, MA Dammert, A Schmitt, ... Nature communications 9 (1), 4655, 2018 | 135 | 2018 |
| Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer F Malchers, F Dietlein, J Schöttle, X Lu, L Nogova, K Albus, ... Cancer discovery 4 (2), 246-257, 2014 | 118 | 2014 |
| Targeting DNA damage response and replication stress in pancreatic cancer SB Dreyer, R Upstill-Goddard, V Paulus-Hock, C Paris, EM Lampraki, ... Gastroenterology 160 (1), 362-377. e13, 2021 | 116 | 2021 |
| Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes K Miyabayashi, LA Baker, A Deschênes, B Traub, G Caligiuri, D Plenker, ... Cancer discovery 10 (10), 1566-1589, 2020 | 112 | 2020 |
| Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients D Plenker, M Bertrand, AJ de Langen, R Riedel, C Lorenz, AH Scheel, ... Clinical Cancer Research 24 (6), 1337-1343, 2018 | 87 | 2018 |
| Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer TT Seppälä, JW Zimmerman, E Sereni, D Plenker, R Suri, N Rozich, ... Annals of surgery 272 (3), 427-435, 2020 | 84 | 2020 |
| Organoid models for translational pancreatic cancer research H Tiriac, D Plenker, LA Baker, DA Tuveson Current opinion in genetics & development 54, 7-11, 2019 | 73 | 2019 |
| Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors D Plenker, M Riedel, J Brägelmann, MA Dammert, R Chauhan, ... Science translational medicine 9 (394), eaah6144, 2017 | 63 | 2017 |
| Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data L Fernandez-Cuesta, R Sun, R Menon, J George, S Lorenz, ... Genome biology 16, 1-11, 2015 | 63 | 2015 |
| Opposing effects of CREBBP mutations govern the phenotype of Rubinstein-Taybi syndrome and adult SHH medulloblastoma DJ Merk, J Ohli, ND Merk, V Thatikonda, S Morrissy, M Schoof, ... Developmental cell 44 (6), 709-724. e6, 2018 | 46 | 2018 |
| Loop-mediated isothermal amplification detection of SARS-CoV-2 and myriad other applications KJM Moore, J Cahill, G Aidelberg, R Aronoff, A Bektaş, D Bezdan, ... Journal of biomolecular techniques: JBT 32 (3), 228, 2021 | 45 | 2021 |
| MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I J Brägelmann, C Lorenz, S Borchmann, K Nishii, J Wegner, L Meder, ... Nature communications 12 (1), 5505, 2021 | 43 | 2021 |
| Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy L Demyan, AN Habowski, D Plenker, DA King, OJ Standring, C Tsang, ... Annals of surgery 276 (3), 450-462, 2022 | 42 | 2022 |
| Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics S Bhatia, M Kramer, S Russo, P Naik, G Arun, K Brophy, P Andrews, ... Cancer research 82 (7), 1174-1192, 2022 | 40 | 2022 |
| Genomic profiling identifies outcome-relevant mechanisms of innate and acquired resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor … S Michels, C Heydt, B van Veggel, B Deschler-Baier, N Pardo, ... JCO precision oncology 3, 1-14, 2019 | 39 | 2019 |
| Discovery of Inter-Domain Stabilizers A Novel Assay System for Allosteric Akt Inhibitors Z Fang, JR Simard, D Plenker, HD Nguyen, T Phan, P Wolle, ... ACS Chemical Biology 10 (1), 279-288, 2015 | 29 | 2015 |
